TrialJournal of neuro-oncology2023

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.

Roy Strowd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.